Loading stock data…
$2.39-0.04 (-1.64%)
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.
Boundless Bio, Inc. in the Healthcare sector is trading at $2.48 with a market capitalization of $65M. Wall Street consensus targets $4.00 (1 analysts), implying a +61.0% move over the next 12 months. The stock is currently 21% below its 52-week high of $3.16, remaining 35.1% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$24.38M↓ | -$14.47M↓ | -$14.00M↑ | -$15.15M↑ | -$17.06M |
| Net Income | -$23.69M↓ | -$13.55M↓ | -$12.88M↑ | -$13.88M↑ | -$15.68M |
Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic...